A
Axiom Therapeutics
AI-powered covalent drug discovery for untreatable cancers
About Axiom Therapeutics
Axiom Therapeutics is a London-based biotechnology company pioneering a new class of precision oncology treatments. Founded in 2024 by University of Cambridge alumni Ryan Geiser and Chris Haggard, the company leverages a proprietary platform that combines machine learning with physics-based simulations to unlock "undruggable" cancer targets.
The company’s core technology is an AI-driven discovery engine designed specifically for covalent inhibitors—drugs that form permanent bonds with their target proteins. by integrating quantum simulation methods with advanced machine learning, Axiom predicts the interaction between small molecules and disease-causing proteins with high accuracy, enabling the design of more potent and selective therapies for hard-to-treat malignancies.
Axiom aims to revolutionize cancer care by identifying novel therapeutic solutions for patients who currently lack effective treatment options. Backed by investors like Cambridge Enterprise Ventures and Plug and Play, the startup is accelerating the development of next-generation medicines that target the underlying molecular drivers of disease.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 8
- Open positions
- None listed
- Dealroom signal
- 81.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Oncology, Drug Development, Research and Development, Molecular, Spinout, AI Drug Discovery
- Technology
- Artificial Intelligence, Deep Tech
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Apr 2025 | $15M | $60M | Dimension Capital Management · Amplify Partners · Zetta Venture Partners · Fenwick & West | ↗ |
| SPINOUT✓Other financing | Aug 2024 | $0 | — | University of Cambridge | ↗ |
Growth signals
Latest recorded traffic for Axiom Therapeutics is 3.1K monthly website visits, up 5066.7% over the last three months. Axiom Therapeutics's team grew 33.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Axiom Therapeutics in the London ecosystem
The Axiom Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Dimension Capital Management
Amplify Partners
Zetta Venture Partners
Fenwick & West
Other known investors5 additional known investors
University of Cambridge
Grow London
Lunar Ventures
Samos Investments
Verve Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Axiom Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Axiom Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










